Brandon BioCatalyst will guide a limited cohort of companies and entrepreneurs on a transformative journey that culminates in the opportunity to attend BIO2024 in San Diego (at your own expense). Brandon BioCatalyst will work with TIQ to provide the Cohort with an opportunity to present at the Queensland Investor Roundtable event at BIO 2024.
The seminar portion of the program is open to all.
What to expect?
📚 A four-part seminar series covering pivotal subjects like pre-commercialization planning, early preclinical development, clinical and regulatory strategy, and company formation, investment, and partnering.
🔧 Beyond Seminars: Practical workshops exploring business planning, CUREator grants, clinical and regulatory development, and BIO preparation and planning.
🤝 You’ll have access to the globally connected Brandon BioCatalyst team, who will help you navigate the early stages of innovation, driving towards commercialization outcomes, including investment and partnerships.
The seminar series portion of the program is open to all.
Tuesday 27 February 2024 – Preparing yourself for clinical translation: An introduction to a Target Product Profile (TPP) & The importance of picking the right target: Perspectives from Pharma and Start up.
Therapeutic development planning, early commercialisation considerations and spin out creation. After lunch the Cohort will have a session on business planning and Target Product Profiles from a Pharmaceutical perspective presented by ex GSK VP and Head of Biology and current Brandon Capital Venture Partner Dr Roberto Solari and Analyst Dr Melissa Byrne.